Iznaga-Escobar N
Center of Molecular Immunology, Havana, Cuba.
Nucl Med Biol. 1998 Jul;25(5):441-7. doi: 10.1016/s0969-8051(98)00008-0.
The increased interest in the availability of radionuclides for therapy has resulted from the recent success and potential importance of radiolabeled antibodies for both diagnosis and therapy. There is a widespread interest in the availability of 188Re for various therapeutic applications, particularly for attachment to tumor-specific monoclonal antibodies for radioimmunotherapy. This review provides a perspective of 188Re-direct labeled MAbs for radioimmunotherapy of solid tumors, normal organ biodistribution, absorbed radiation doses to normal organs and tumors, and the toxicity to bone marrow and normal tissues. Methods for calculation of mean absorbed radiation doses to the whole body, various normal organs, and tumors have been developed using source-organ residence times and the methods developed by the Medical Internal Radiation Dose (MIRD) committee. The toxicity for 188Re-labeled antibodies is predominantly hematopoietic, with platelets and white blood cells being most sensitive to the effects of radiation. Rhenium-188 would be the isotope of choice for radioimmunotherapeutic applications because of cost, availability, and favorable radiation characteristics. Rhenium-188 has a half-life of 16.9 h and maximum beta energy of 2.118 MeV. This isotope is particularly attractive because it can be supplied conveniently from 188W/188Re-radionuclide generator system.
对用于治疗的放射性核素可用性的兴趣增加，源于放射性标记抗体在诊断和治疗方面最近取得的成功及其潜在的重要性。人们对188Re在各种治疗应用中的可用性广泛关注，特别是用于连接肿瘤特异性单克隆抗体进行放射免疫治疗。本文综述了188Re直接标记的单克隆抗体在实体瘤放射免疫治疗中的应用前景、正常器官生物分布、正常器官和肿瘤的吸收辐射剂量以及对骨髓和正常组织的毒性。利用源器官停留时间和医学内照射剂量（MIRD）委员会开发的方法，已开发出计算全身、各种正常器官和肿瘤平均吸收辐射剂量的方法。188Re标记抗体的毒性主要是造血毒性，血小板和白细胞对辐射影响最为敏感。由于成本、可用性和良好的辐射特性，铼-188将是放射免疫治疗应用的首选同位素。铼-188的半衰期为16.9小时，最大β能量为2.118兆电子伏特。这种同位素特别有吸引力，因为它可以方便地从188W/188Re放射性核素发生器系统获得。
